Neuromodulatory properties of flavonoids from Persea americana Peel: Role in CNS redox homeostasis and neurobehavioral markers
Objective: Isolating flavonoids from Peel of Persea americana fruits & testing their effects on CNS redox homeostasis culminating in neurobehavioural amelioration among rats. Background: Cellular…Neuromodulatory propensity of Ginko biloba to offset rotenone induced behaviour and biochemical alteration
Objective: The aim of present study was to evaluate neuromodulatory propensity of Gingko Biloba in rotenone induced Mice Model of Parkinson Disease in terms of…Rotigotine protects dopaminergic neurons by targeting serotonin 1A receptors on astrocytes
Objective: In this study, we examined neuroprotective effects of rotigotine and involvement of serotonin 1A (5-HT1A) receptors on astrocytes in neuroprotective action of the drug…Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
Objective: To evaluate the effect of Mate leaves extracts on the survival and maturation of dopaminergic neurons in vitro. Background: Parkinson's disease (PD) is caused…Neuromodulatory role of subthalamic nucleus deep brain stimulation in Parkinson’s disease patients
Objective: The aim of study was to evaluate the impact of subthalamic nucleus deep brain stimulation (STN-DBS) on the motor disabilities and cognitive alterations in…Oral treatment with sphingosine-1-phosphate receptors modulator prevents Parkinson symptoms concomitantly to reduced brain inflammation in MPTP mouse models
Objective: Here we explore the efficacy of an oral treatment with Fingolimod (FTY720), a selective sphingosine-1-phosphate receptors modulator, to prevent MPTP induced nigrostriatal loss and…The NIC-PD-study –A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson‘s disease in Germany and N. America
Objective: To evaluate the disease modifying potential of transdermal (TD) nicotine in early Parkinson’s disease (PD). For this explanatory purpose, the primary endpoint was the…What makes a successful Phase 2 study: An evaluation of Parkinson’s neuroprotective trial design over the last 5 years
Objective: To evaluate variation in Phase 2 and 3 Parkinson’s disease (PD) neuroprotective trial designs and identify key trial design features in Phase 2 studies…A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease
Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…The Akt/mTOR/P70S6K/4EB-P1 signaling pathway is activated by metformin in a toxin-induced cellular model of Parkinson’s disease
Objective: To investigate the effects of metformin on the Akt/mTOR/P70S6K/4EB-P1 signaling pathway in a cellular model of Parkinson’s disease (PD). Background: Metformin is a drug…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 13
- Next Page »